Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Deciphera Pharmaceuticals, Inc.

< Previous 1 2 Next >
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss DCC-3116 and Vimseltinib Data Presented at ESMO Congress 2022
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinical Oncology
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Tickers DCPH
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.